ライフサイエンスコーパス: transarterial chemoembolization

1 cellular carcinoma lesions treated with TACE transarterial chemoembolization .

2 t than those seen after thermal ablation and transarterial chemoembolization.

3 long with imaging findings of ablation after transarterial chemoembolization.

4 atocellular carcinoma underwent conventional transarterial chemoembolization.

5 r unresectable disease > 3 cm in diameter is Transarterial Chemoembolization.

6 treated with local interventions, including transarterial chemoembolization.

7 atients undergoing surgical resection (16%), transarterial chemoembolization (19%), or radiotherapy (

8 lus ablation (11.1%), ablation alone (7.9%), transarterial chemoembolization (9.5%), and whole-liver

9 rvival when ICI therapies were combined with transarterial chemoembolization, although data regarding

10 s with hepatocellular carcinoma treated with transarterial chemoembolization and includes 377 handcra

11 Minimally invasive therapies such as transarterial chemoembolization and radiofrequency ablat

12 ing tissue diagnosis, and proven efficacy of transarterial chemoembolization and sorafenib as palliat

13 when combining transplant with preoperative transarterial chemoembolization and/or perioperative sys

14 ation, hepatic artery infusion chemotherapy, transarterial chemoembolization, and radioembolization,

15 After progression on chemotherapy, HAIP, transarterial chemoembolization, and transarterial radio

16 hepatocellular carcinoma who underwent TACE transarterial chemoembolization before surgery.

17 tified patients with a survival benefit from transarterial chemoembolization before therapy.

18 Each patient underwent two sessions of transarterial chemoembolization between February 2013 an

19 paring yttrium-90 microsphere treatment with transarterial chemoembolization by using the Cancer of t

20 yndrome from Lipiodol embolization following transarterial chemoembolization can occur even with smal

21 Transarterial chemoembolization (cTACE) has been shown t

22 Conventional transarterial chemoembolization (cTACE) is a guideline-a

23 Conventional transarterial chemoembolization (cTACE) is used to treat

24 r carcinoma (HCC) is treated by conventional transarterial chemoembolization (cTACE) using cone-beam

25 ar patient cohort who underwent conventional transarterial chemoembolization (cTACE).

26 d oil to liver tumors following conventional transarterial chemoembolization (cTACE).

27 iocarcinoma (ICC) who underwent conventional transarterial chemoembolization (cTACE).

28 ver tumor viability after drug-eluting beads transarterial chemoembolization (DEB-TACE).

29 odol embolization in a patient who underwent transarterial chemoembolization for hepatocellular carci

30 Yttrium-90 achieved higher DS success than transarterial chemoembolization in AC (74% vs. 65%; p <0

31 Yttrium-90 attained higher DS success than transarterial chemoembolization in AC.

32 Transarterial chemoembolization is a widely used therapy

33 Transarterial chemoembolization is accepted therapy for

34 Drug-eluting beads coated with irinotecan transarterial chemoembolization is associated with high

35 For intermediate-stage HCC, transarterial chemoembolization is the mainstay of treat

36 For intermediate-stage HCC, transarterial chemoembolization is the mainstay of treat

37 fore LT with a multimodal approach combining transarterial chemoembolization, liver resection, radiof

38 e for the routine utilization of CBCT during transarterial chemoembolization of liver cancer.

39 , respectively, as part of the institutional transarterial chemoembolization protocol).

40 d time to progression when used as part of a transarterial chemoembolization regimen for unresectable

41 rc cone-beam CT (during the first and second transarterial chemoembolization sessions, respectively,

42 RT as bridging therapy, with comparison with transarterial chemoembolization (TACE) and high-intensit

43 lly insufficient future liver remnant (FLR), transarterial chemoembolization (TACE) and portal vein e

44 t patterns including receipt of sorafenib or transarterial chemoembolization (TACE) by HCC-associated

45 outcomes of radiation segmentectomy (RS) and transarterial chemoembolization (TACE) combined with mic

46 Despite transarterial chemoembolization (TACE) for hepatocellula

47 on and/or ablation, and 18 were managed with transarterial chemoembolization (TACE) frequently (n = 1

48 Lipiodol-based transarterial chemoembolization (TACE) has been performe

49 n the detection of residual viable HCC after transarterial chemoembolization (TACE) in a prospective

50 induced by transarterial embolization (TAE)/transarterial chemoembolization (TACE) in a state of cel

51 curate disease monitoring is essential after transarterial chemoembolization (TACE) in hepatocellular

52 TARE was compared with transarterial chemoembolization (TACE) in nine studies o

53 e to guide the decision for retreatment with transarterial chemoembolization (TACE) in patients with

54 re patient outcomes of HDR brachytherapy and transarterial chemoembolization (TACE) in patients with

55 sity focused ultrasound (HIFU) combined with transarterial chemoembolization (TACE) in treating pedia

56 Transarterial chemoembolization (TACE) is an image-guide

57 Transarterial chemoembolization (TACE) is currently reco

58 Transarterial chemoembolization (TACE) is the main treat

59 Background Transarterial chemoembolization (TACE) is the recommende

60 treated by radiofrequency ablation (RFA) +/- transarterial chemoembolization (TACE) or surgical resec

61 rine liver metastases (NELM) after the first transarterial chemoembolization (TACE) procedure.

62 Background Despite transarterial chemoembolization (TACE) serving as the fi

63 Transarterial chemoembolization (TACE) using lipiodol-ba

64 Despite transarterial chemoembolization (TACE) was recommended a

65 Transarterial chemoembolization (TACE) was similarly app

66 Idarubicin-loaded beads for transarterial chemoembolization (TACE) were previously e

67 To evaluate safety and efficacy of combined transarterial chemoembolization (TACE) with doxorubicin-

68 those 15 rabbits, six underwent conventional transarterial chemoembolization (TACE), four underwent c

69 s well as to compare tolerability of SRFA to transarterial chemoembolization (TACE), hepatic resectio

70 ween FAD subtypes and response to sorafenib, transarterial chemoembolization (TACE), immune checkpoin

71 (MELD) score >10, and absence of neoadjuvant transarterial chemoembolization (TACE).

72 tumor necrosis after drug-eluting bead (DEB) transarterial chemoembolization (TACE).

73 ath with transarterial embolization (TAE) or transarterial chemoembolization (TACE).

74 hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE).

75 ma (HCC) results in different outcomes after transarterial chemoembolization (TACE).

76 ermediate- and advanced-stage HCC to undergo transarterial chemoembolization (TACE).

77 hepatic resection, radiofrequency ablation, transarterial chemoembolization, transarterial chemoinfu

78 or hepatocellular carcinoma (HCC), including transarterial chemoembolization, transarterial radioembo

79 benefit of radical therapies, compared with transarterial chemoembolization, was substantial (5-year

80 Background Transarterial chemoembolization with cytotoxic drugs is

81 llular carcinoma (HCC) patients treated with transarterial chemoembolization with drug-eluting beads

82 l embolization, intraarterial chemoinfusion, transarterial chemoembolization with or without drug-elu

83 To evaluate the safety and efficacy of transarterial chemoembolization with radio-paque doxorub